Related Experiment Video

Updated: Jun 11, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway

Ren Tingting1, Guo Wei, Peng Changliang

  • 1Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.

Cancer Biology & Therapy
|July 2, 2010
PubMed

Insights

Arsenic trioxide (As(2)O(3)) inhibits osteosarcoma cell adhesion and metastasis by affecting the MAPK signaling pathway. This traditional Chinese medicine compound shows promise in reducing cancer cell invasion and motility.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Arsenic trioxide (As(2)O(3)) is a component of traditional Chinese medicine with known anticancer properties.
  • Previous research indicates As(2)O(3) induces apoptosis in various cancer cells.
  • Studies on As(2)O(3)'s effects on osteosarcoma are limited.

Purpose of the Study:

  • To investigate the inhibitory effects of As(2)O(3) on osteosarcoma cell adhesion, migration, and invasion.
  • To elucidate the molecular mechanisms underlying As(2)O(3)'s action in osteosarcoma cells, focusing on the MAPK pathway.

Main Methods:

  • Cell adhesion, migration, and invasion assays were performed on HOS and MNNG osteosarcoma cell lines.
  • Western blotting was used to analyze the impact of As(2)O(3) on MMP-9 activity and MAPK pathway signaling.
  • Experiments involved varying concentrations of As(2)O(3) and using MEK-specific inhibitors (U0126).

Main Results:

  • As(2)O(3) significantly inhibited osteosarcoma cell motility, migration, and invasion in a dose-dependent manner (0.5-2 μM).
  • Treatment with As(2)O(3) induced cytoskeletal rearrangements in cancer cells.
  • As(2)O(3) suppressed the phosphorylation of ERK1/2 and MEK, key components of the MAPK pathway.
  • Combined treatment with As(2)O(3) and a MEK inhibitor further reduced cell invasion.

Conclusions:

  • Arsenic trioxide effectively inhibits the invasiveness of HOS and MNNG osteosarcoma cells.
  • The observed inhibitory effects are, at least partly, mediated by the inactivation of the MAPK signaling pathway.
  • As(2)O(3) demonstrates potential as a therapeutic agent for osteosarcoma by targeting cell metastasis.

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...